Viral Vector Manufacturing Market Top Key Players Analysis, Business Economic Outlook, Revenue, Share, Global Size, New Investments And Forecast 2023

Viral Vector Manufacturing Market Overview:The Viral Vector Manufacturing Market is projected to reach USD 815.8 million by 2023 from USD 327.8 million in 2018, at a CAGR of 20.0% during the forecast period. This market is consolidated in nature with a few global players. In 2017, Lonza (Switzerland), Merck (Germany), and Oxford BioMedica (UK), were the top three players in the viral vector manufacturing market.
Lonza (Switzerland) was the leading player in the viral vector manufacturing market in 2017. The company adopts organic as well as inorganic growth strategies to maintain its dominant position in the market. It entered into agreements with leading gene therapy companies to manufacture their gene therapy products for clinical and commercial use. The company expanded its manufacturing capabilities in the US in 2018 and acquired a leading cell and gene therapy manufacturer in the Netherlands in 2017 to enhance its market presence. Lonza also focuses on seeking growth opportunities in the emerging markets of APAC.Request For Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=89341986 The genetic disorders segment is expected to grow at the highest CAGR during the forecast period
Based on diseases, the global viral vector manufacturing market is segmented into cancer, genetic disorders, infectious diseases, and other diseases. During the forecast period, the genetic disorders segment is expected to grow at the highest CAGR in the market. The accelerated research activities on various genetic disorders such as hemophilia A and B, sickle cell anemia, and Huntington’s disease and a robust gene therapy pipeline in the last phase of drug development is fueling the growth of this segment.
The gene therapy segment is expected to account for the largest share of viral vector manufacturing market in 2018
Based on application, the global viral vector manufacturing market is segmented into gene therapy and vaccinology. In 2018, the gene therapy segment is expected to hold the largest share in this market and this segment is also expected to grow at the highest rate during the forecast period. The large share and fast growth of this segment can be attributed to the large number of clinical trials conducted for gene therapy on target diseases such as cancer, neurodegenerative diseases, and cardiovascular diseases globally.Download PDF: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89341986 Market Segmentation:Viral vector manufacturing Market, by Type
Retroviral Vectors
Adenoviral Vectors
Adeno-associated Viral Vectors
Other Viral Vectors
Viral vector manufacturing Market, by Disease
Cancers
Genetic Disorders
Infectious diseases
Other Diseases
Viral vector manufacturing Market, by Application
Gene Therapy
Vaccinology
Viral vector manufacturing Market, by End User
Pharmaceutical and Biopharmaceutical Companies
Research InstitutesDetailed Information: https://www.marketsandmarkets.com/Market-Reports/viral-vector-manufacturing-market-89341986.html Key Players:

Some other important players in the global viral vector manufacturing market include CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), Spark Therapeutics (US), REGENXBIO (US), FinVector (Finland), Novasep (France), Kaneka Eurogentec (Japan), and MassBiologics (US). These companies also have well-established viral vector manufacturing capabilities and are focused on expanding their market reach through collaborations with cell and gene therapy companies.About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model — GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com